Unpublished activities that were noteworthy included CNR1 inhibition of losartan (AC50 = 1.2 nM) and glipizide (AC50 = 19 nM), which may contribute to their therapeutic effect in treating hypertension and metabolic syndrome (the CNR1 antagonist rimonabant is used in the management of obesity18). Here, CNR1 is linked to hypertensive disorder.